Santhera Pharmaceuticals (Switzerland) Analysis
| SANN Stock | CHF 8.00 0.10 1.27% |
Santhera Pharmaceuticals Holding is overvalued with Real Value of 7.07 and Hype Value of 8.0. The main objective of Santhera Pharmaceuticals stock analysis is to determine its intrinsic value, which is an estimate of what Santhera Pharmaceuticals Holding is worth, separate from its market price. There are two main types of Santhera Pharmaceuticals' stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Santhera Pharmaceuticals' performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Santhera Pharmaceuticals' stock to identify patterns and trends that may indicate its future price movements.
The Santhera Pharmaceuticals stock is traded in Switzerland on SIX Swiss Exchange, with the market opening at 09:00:00 and closing at 17:30:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in Switzerland. Santhera Pharmaceuticals is usually not traded on National Day, Christmas Day, St . Stephen 's Day, New Year 's Day, Berchtoldstag, Good Friday, Easter Monday, International Workers ' Day. Santhera Stock trading window is adjusted to Europe/Zurich timezone.
Santhera |
Santhera Stock Analysis Notes
About 19.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 1.63. Santhera Pharmaceuticals last dividend was issued on the 8th of September 2022. The entity had 10:1 split on the 2nd of July 2023. Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for orphan and other diseases with high unmet medical needs in the European countries. Santhera Pharmaceuticals Holding AG is headquartered in Pratteln, Switzerland. SANTHERA N operates under Biotechnology classification in Switzerland and is traded on Switzerland Exchange. It employs 114 people. To find out more about Santhera Pharmaceuticals Holding contact the company at 41 61 906 89 50 or learn more at https://www.santhera.com.Santhera Pharmaceuticals Investment Alerts
| Santhera Pharmaceuticals generated a negative expected return over the last 90 days | |
| Santhera Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Santhera Pharmaceuticals has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations | |
| Net Loss for the year was (55.53 M) with loss before overhead, payroll, taxes, and interest of (5.36 M). | |
| Santhera Pharmaceuticals Holding has accumulated about 21.21 M in cash with (37.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.07. | |
| Roughly 19.0% of the company outstanding shares are owned by corporate insiders |
Santhera Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 50.45 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Santhera Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Santhera Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Technical Drivers
As of the 23rd of November, Santhera Pharmaceuticals has the Risk Adjusted Performance of (0.05), variance of 4.58, and Coefficient Of Variation of (1,373). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Santhera Pharmaceuticals, as well as the relationship between them. Please validate Santhera Pharmaceuticals mean deviation, standard deviation, information ratio, as well as the relationship between the coefficient of variation and variance to decide if Santhera Pharmaceuticals is priced more or less accurately, providing market reflects its prevalent price of 8.0 per share.Santhera Pharmaceuticals Price Movement Analysis
The output start index for this execution was two with a total number of output elements of fifty-nine. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Santhera Pharmaceuticals middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Santhera Pharmaceuticals. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Santhera Pharmaceuticals Outstanding Bonds
Santhera Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Santhera Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Santhera bonds can be classified according to their maturity, which is the date when Santhera Pharmaceuticals Holding has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View |
Santhera Pharmaceuticals Predictive Daily Indicators
Santhera Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Santhera Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Santhera Pharmaceuticals Forecast Models
Santhera Pharmaceuticals' time-series forecasting models are one of many Santhera Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Santhera Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Santhera Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Santhera Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Santhera shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Santhera Pharmaceuticals. By using and applying Santhera Stock analysis, traders can create a robust methodology for identifying Santhera entry and exit points for their positions.
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for orphan and other diseases with high unmet medical needs in the European countries. Santhera Pharmaceuticals Holding AG is headquartered in Pratteln, Switzerland. SANTHERA N operates under Biotechnology classification in Switzerland and is traded on Switzerland Exchange. It employs 114 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Santhera Pharmaceuticals to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Money Managers Now
Money ManagersScreen money managers from public funds and ETFs managed around the world |
| All Next | Launch Module |
Additional Tools for Santhera Stock Analysis
When running Santhera Pharmaceuticals' price analysis, check to measure Santhera Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Santhera Pharmaceuticals is operating at the current time. Most of Santhera Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Santhera Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Santhera Pharmaceuticals' price. Additionally, you may evaluate how the addition of Santhera Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.